@article{4c9a9414c9cc4fbdb3d772c27ad5916c,
title = "The Pancreatic β-cell Response to Secretory Demands and Adaption to Stress",
abstract = "Pancreatic β cells dedicate much of their protein translation capacity to producing insulin to maintain glucose homeostasis. In response to increased secretory demand, β cells can compensate by increasing insulin production capability even in the face of protracted peripheral insulin resistance. The ability to amplify insulin secretion in response to hyperglycemia is a critical facet of β-cell function, and the exact mechanisms by which this occurs have been studied for decades.To adapt to the constant and fast-changing demands for insulin production, β cells use the unfolded protein response of the endoplasmic reticulum. Failure of these compensatory mechanisms contributes to both type 1 and 2 diabetes. Additionally, studies in which β cells are “rested” by reducing endogenous insulin demand have shown promise as a therapeutic strategy that could be applied more broadly. Here, we review recent findings in β cells pertaining to the metabolic amplifying pathway, the unfolded protein response, and potential advances in therapeutics based on β-cell rest.",
keywords = "beta cell rest, endoplasmic reticulum stress, insulin secretion, pancreatic islet beta cell, unfolded protein response",
author = "Michael Kalwat and Donalyn Scheuner and Karina Rodrigues-Dos-Santos and Eizirik, {Decio L.} and Cobb, {Melanie H.}",
note = "Funding Information: Thank you to members of the Kalwat laboratory, Fiona Armoo and Gitanjali Roy, for helpful discussions and comments. The authors also thank Andrew Templin (Indiana Biosciences Research Institute) and Scott Soleimanpour (University of Michigan) for critiques and suggestions during the preparation of the manuscript. Human pancreatic islet expression data were accessed via the TIGER Data Portal (http://tiger.bsc.es) and the T2DSystems Consortium, and via the Huising laboratory (http://huisinglab.com/diabetes_2019/index. html) (274). M.A.K. is supported as a Lilly Scholar in the Lilly Diabetes Center of Excellence at Indiana Biosciences Research Institute (IBRI) and by an award from the Diabetes Research Connection. D.L.S. is supported by the IBRI. M.H.C. is supported by National Institutes of Health R37 DK34128 and Welch I1243. D.L.E. acknowledges the support of grants from the Welbio-FNRS (Fonds National de la Recherche Scientifique; WELBIO-CR-2019C-04), Belgium; the Innovate2CureType1-Dutch Diabetes Research Foundation (DDRF), Holland; the Juvenile Diabetes Research Foundation (JDRF; 2-SRA-2019-834-S-B); the National Institutes of Health (HIRN-CBDS) grant U01 DK127786, USA; startup funds from the IBRI, Indianapolis, IN, USA; and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement numbers 115797 (INNODIA) and 945268 (INNODIA HARVEST), supported by the European Union's Horizon 2020 research and innovation program. These Joint Undertakings receive support from the Union's Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations, JDRF, and The Leona M. and Harry B. Helmsley Charitable Trust. Publisher Copyright: {\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.",
year = "2021",
month = nov,
day = "1",
doi = "10.1210/endocr/bqab173",
language = "English (US)",
volume = "162",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "11",
}